---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-004311"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T18:40:52.451378+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Imunon's EVP and CMO Nicholas Borys to depart Feb 28, 2023

## Summary
- Nicholas Borys, EVP and Chief Medical Officer, will separate effective February 28, 2023.
- Borys will receive salary continuation and COBRA premiums for up to 12 months; benefits cease or reduce if new employment is found.
- No replacement for the CMO role has been announced at this time.

## SEC filing metadata
- accession: 0001493152-23-004311
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315223004311/0001493152-23-004311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315223004311/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-004311
- JSON: https://secwatch.observer/filing/0001493152-23-004311.json
- Plain text: https://secwatch.observer/filing/0001493152-23-004311.txt

## Key facts
- Executive change
  Nicholas Borys departed as Executive Vice President and Chief Medical Officer at Imunon, Inc..
  - Action: separated
  - Role: Executive Vice President and Chief Medical Officer
  source text: On February 10, 2023, Imunon, Inc., a Delaware corporation (“Imunon”), announced that Nicholas Borys, its Executive Vice President and Chief Medical Officer, would separate from Imunon effective as of February 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315223004311/0001493152-23-004311-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.